Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

Overall, it found that patients could lose up to a fifth of their body weight using the injectable GLP-1s, but put it back on at a rate of 0.8 kg a month after the treatment stopped, which means that ...

The alliance with Paris, France-based Iktos could be worth more than €1 billion in upfront, research funding, and milestone ...

Judges in the First US Circuit Court of Appeals in Boston have rejected an effort to overturn last month's injunction on the ...

OpenAI has announced ChatGPT Health, which promises to bring users' medical records and health and wellness apps like Apple ...

A report in the Wall Street Journal, citing people familiar with the matter, suggested an announcement of a transaction could ...

The ISPOR Glasgow panel conveyed a constructive, forward looking mood: JCA can work – and work better over time – if ...

Beyond the opportunities for start-ups, this change making direct primary care an eligible HSA expense represents a significant step in fighting chronic disease. This is because it allows the primary ...

Bayer's agrochemicals unit Monsanto has filed lawsuits in the US against the manufacturers of mRNA-based COVID-19 vaccines, ...

Hutchmed is preparing to file for approval of a drug for the rare autoimmune disorder warm antibody autoimmune haemolytic ...

Eli Lilly is reported to be eyeing a $1 billion-plus takeover of Ventyx Biosciences that, if confirmed, suggests 2026 could ...

In what is thought to be the first major pharma M&A deal of the year, Amgen has bought Oxford, UK-based biotech Dark Blue ...